DEFA3 and Sepsis: To examine the therapeutic potential of the blocking antibody in established sepsis, we treated mice with HCN of DEFA1/DEFA3 at an initial time of 12 h post-CLP and thereafter at 36 and 60 h (Fig. 6C).